Novel Heterocyclic Dpp-4 Inhibitors for the Treatment of Type 2 Diabetes.
Sutton, J.M., Clark, D.E., Dunsdon, S.J., Fenton, G., Fillmore, A., Harris, N.V., Higgs, C., Hurley, C.A., Krintel, S.L., Mackenzie, R.E., Duttaroy, A., Gangl, E., Maniara, W., Sedrani, R., Namoto, K., Ostermann, N., Gerhartz, B., Sirockin, F., Trappe, J., Hassiepen, U., Baeschlin, D.K.(2012) Bioorg Med Chem Lett 22: 1464
- PubMed: 22177783 
- DOI: https://doi.org/10.1016/j.bmcl.2011.11.054
- Primary Citation of Related Structures:  
4A5S - PubMed Abstract: 
Novel deazaxanthine-based DPP-4 inhibitors have been identified that are potent (IC(50) <10nM) and highly selective versus other dipeptidyl peptidases. Their synthesis and SAR are reported, along with initial efforts to improve the PK profile through decoration of the deazaxanthine core. Optimisation of compound 3a resulted in the identification of compound (S)-4i, which displayed an improved in vitro and ADME profile. Further enhancements to the PK profile were possible by changing from the deazahypoxanthine to the deazaxanthine template, culminating in compound 12g, which displayed good ex vivo DPP-4 inhibition and a superior PK profile in rat, suggestive of once daily dosing in man.
Organizational Affiliation: 
Argenta Discovery 2009 Ltd, Harlow CM19 5TR, UK. jon.sutton@glpg.com